Five Prime Therapeutics Stock Price - FPRX

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Five Prime Therapeutics Inc FPRX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.06 1.88% 3.26 3.37 3.18 3.20 3.20 13:42:56
Bid Price Ask Price Spread Spread % News
3.26 3.27 0.01 0.31% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,876 208,124 $ 3.24 $ 674,182 356,888 3.18 - 13.97
Last Trade Time Type Quantity Stock Price Currency
13:43:36 100 $ 3.26 USD

Five Prime Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 119.91M 36.78M $ -140.45M -4.11 - 35.57M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 3.30%

more financials information »

Five Prime Therapeutics News

Loading Messages....

Latest FPRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical FPRX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.834.033.183.53265,115-0.57-14.88%
1 Month4.064.383.183.88335,331-0.80-19.7%
3 Months5.606.383.184.31314,248-2.34-41.79%
6 Months9.139.493.185.42370,651-5.87-64.29%
1 Year11.8413.973.187.80329,982-8.58-72.47%
3 Years57.8160.983.1821.51379,684-54.55-94.36%
5 Years15.3460.983.1826.92390,446-12.08-78.75%

Five Prime Therapeutics Description

Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.


Your Recent History
NASDAQ
FPRX
Five Prime..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.